Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | CTSC | P53634 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | CLPP | Q16740 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409828 | 0.87 | NPC1 (0.56) | NPC1RAB9AKMT2AEPHX2KDM5A | |
| SCHEMBL3317199 | 0.86 | GLA (0.60) | RAB9AKMT2AEPHX2KDM5AGRM5 | |
| SCHEMBL3318912 | 0.86 | NPC1 (0.62) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL3320973 | 0.86 | GLA (0.60) | RAB9AKMT2AEPHX2KDM5AGRM5 | |
| SCHEMBL3318918 | 0.86 | NPC1 (0.62) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL3316785 | 0.86 | MEN1 (0.57) | KMT2ACTSBCTSKEPHX2KDM5A | |
| SCHEMBL3316788 | 0.86 | MEN1 (0.57) | KMT2ACTSBCTSKEPHX2KDM5A | |
| SCHEMBL2825567 | 0.85 | NPC1 (0.61) | NPC1RAB9AKMT2AEPHX2GFER | |
| SCHEMBL2825568 | 0.85 | NPC1 (0.61) | NPC1RAB9AKMT2AEPHX2GFER | |
| SCHEMBL4680045 | 0.83 | GRM5 (0.46) | NPC1RAB9AKMT2ACTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2030970-A1 | Allosteric modulators of metabotropic glutamate receptors | ADDEX Pharma S.A. (CH) | 2009-03-04 | — | — | EP | claimed |
| EP-1685105-B1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2008-10-15 | — | — | EP | claimed |
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | claimed |
| CN-1898206-A | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2007-01-17 | — | — | CN | claimed |
| EP-1685105-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2006-08-02 | — | — | EP | claimed |
| WO-2005044797-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-05-19 | — | — | WO | claimed |
| US-8163775-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-04-24 | — | — | US | disclosed |
| CN-102336749-A | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA | 2012-02-01 | — | — | CN | disclosed |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-01-26 | — | — | US | disclosed |
| US-8030331-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2011-10-04 | — | — | US | disclosed |
| CN-1898206-B | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA | 2011-09-14 | — | — | CN | disclosed |
| US-20110112143-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-05-12 | — | — | US | disclosed |
| US-7834035-B2 | Schizophrenia and related disorders; positive allosteric modulators of mGluR5; {3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone for example; compounds are all contain a 5-(1-carbonylpiperidin-3-yl)-1,2,4-oxadiazole moiety | ADDEX PHARMA SA (CH) | 2010-11-16 | — | — | US | disclosed |
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | disclosed |
| CN-1898206-A | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2007-01-17 | — | — | CN | disclosed |
| EP-1685105-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044797-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM1 | NPC1 2108/4885RAB9A 1437/4885KMT2A 1613/4885 |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | NPC1 2108/4885RAB9A 1437/4885KMT2A 1613/4885 |
| US-20110112143-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | NPC1 2108/4885RAB9A 1437/4885KMT2A 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.